SCHEMBL1967207

SCHEMBL1967207

Cc1ccccc1-c1cccc2nc(-c3ccccc3Cl)c(Nc3ccccc3)n12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 15/20 0.47
TP53 P04637 11/20 0.47
SMN1; SMN2 Q16637 9/20 0.46
MAPT P10636 8/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 3/20 0.43
PKLR P30613 3/20 0.43
POLB P06746 2/20 0.40
HTT P42858 1/20 0.40
PPP1CA P62136 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
FLT1 P17948 1/20 0.38
CDK8 P49336 1/20 0.38
CDK9 P50750 1/20 0.38
LIMK1 P53667 1/20 0.38
ROCK1 Q13464 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1967089 0.85 GAA (0.62) GAATP53SMN1; SMN2MAPTKDM4E
SCHEMBL1965240 0.83 GAA (0.53) GAATP53SMN1; SMN2MAPTKDM4E
SCHEMBL1967015 0.81 PKM (0.53) GAATP53SMN1; SMN2MAPTKDM4E
SCHEMBL1964935 0.81 GAA (0.51) GAATP53SMN1; SMN2MAPTKDM4E
SCHEMBL1967204 0.79 ALOX5 (0.45) GAATP53SMN1; SMN2MAPTKDM4E
SCHEMBL1968357 0.78 GAA (0.51) GAATP53SMN1; SMN2MAPTKDM4E
SCHEMBL1966488 0.77 GAA (0.46) GAATP53SMN1; SMN2MAPTKDM4E
SCHEMBL13031463 0.77 SMN1; SMN2 (0.76) GAATP53SMN1; SMN2MAPTKDM4E
SCHEMBL1970576 0.77 GAA (0.47) GAATP53SMN1; SMN2MAPTKDM4E
SCHEMBL13031456 0.77 GAA (0.65) GAATP53SMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501767-B2 Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors CSIR (ZA) 2013-08-06 US claimed
US-20110312957-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS CSIR (ZA) 2011-12-22 US claimed
EP-2334675-B1 IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS CSIR (ZA) 2014-03-26 EP disclosed
US-8501767-B2 Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors CSIR (ZA) 2013-08-06 US disclosed
US-20110312957-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS CSIR (ZA) 2011-12-22 US disclosed
EP-2334675-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS CSIR (ZA) 2011-06-22 EP disclosed
WO-2010032195-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS CSIR (ZA) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312957-A1 IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS TYMP, IMPDH1, DPYD GAA 441/4885TP53 4006/4885SMN1; SMN2 3745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.